LMP744 treatment increased the level of nuclear γH2AX in tumor cells above 4% NAP (i.e., the assay threshold to exceed biological variability [15, 19, 29]) only in patient 29 with SLFN11-positive SCLC (Fig. 4A), and importantly, this γH2AX increase was accompanied by an increase in co-localized cytoplasmic cCASP3 (Fig. 4B), indicative of apoptosis [29]. The gene discussed is SLFN11; the disease is neoplasm.